DR. EDWIN CADMAN JOINS BOARD AT CYTOTHERAPEUTICS
DR. EDWIN CADMAN JOINS BOARD AT CYTOTHERAPEUTICS PROVIDENCE, R.I., Oct. 29 /PRNewswire/ -- CytoTherapeutics, Inc.
(NASDAQ: CTII) has appointed Edwin C. Cadman, M.D., of Yale University School of Medicine, to its board of directors.
Dr. Cadman has been Ensign Professor and chairman of the department of Internal Medicine at Yale University since 1987. Previously, he had been vice-chairman of the department of medicine and chief of hematology and oncology, as well as Professor and director of the cancer Research Institute at the University of California, San Francisco. While at the University of California, Cadman also held positions as the David A. Wood Professor of Tumor Biology and the American Cancer Society Professor of Oncology. "As we move closer to the clinic with our existing cell therapy products in development and the potential applications of our technology expand, it is appropriate to increase the medical base of the board. Dr. Cadman's internationally recognized expertise in pharmacology and his understanding of cell growth, combined with extensive medical experience, will greatly enhance the development of all our products," said Seth A. Rudnick, M.D., president and chief executive officer of CytoTherapeutics. Since 1988, Cadman has held a position on the advisory board of the Vincent T. Lombardi Cancer Research Center. He has also been president of the American Federation for Clinical Research. In addition to having served on Schering Corporation's Interferon Scientific Advisory board, Cadman has also been associated with the Pharmacology Program at Roswell Park Memorial Institute and the Institute of Medicine's Agent Orange Study at the Center for Disease Control in Washington, D.C. Cadman received his medical degree at the University of Oregon and served his internship and residency at Stanford University Hospital. He also received a Fellowship in Oncology at Yale University School of Medicine. CytoTherapeutics, Inc., of Providence, R.I. was formed in 1989 to develop cellular therapies based on proprietary membrane encapsulation technologies licensed from Brown and Washington Universities. The company's product development candidates include its NeuroCRIB(tm) for the treatment of Parkinson's disease, EndoCRIB(tm) for the treatment of Type I diabetes and CereCRIB(tm) for the treatment of severe, chronic pain. -0- 10/29/92 /CONTACT: Thomas G. Wiggans, chief financial officer, 401-272-3310 ext. 152, or Elizabeth Razee, communications coordinator of CytoTherapeutics, Inc., 401-272-3310 ext. 132/ (CTII) CO: CytoTherapeutics ST: Rhode Island IN: MTC SU: PER
DH -- NE002 -- 6395 10/29/92 08:38 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 29, 1992|
|Previous Article:||JOHNSON CONTROLS REPORTS RECORD YEAR-END RESULTS|
|Next Article:||LINCOLN N.C. REALTY FUND ADJOURNS UNTIL NOV. 25, 1992|